No increase in adverse events during aliskiren use among Ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers
Gilbert CJ, Gomes T, Mamdani MM, Hellings C, Yao Z, Garg AX, Wald R, Harel Z, Juurlink DN. Can J Cardiol. 2013; 29(5):586-91. Epub 2013 Apr 1.